Xenograft recipients and the right to withdraw from a clinical trial
Bibliographic Data
| ID | 21504066 |
|---|---|
| Authors | Chris Bobier (0000-0003-4194-4721, Department of Theology and Philosophy, Associate Director, Hendrickson Institute for Ethical Leadership St. Mary's University of Minnesota Winona Minnesota USA, corresponding author), Daniel J Hurst (0000-0003-0592-2592, Department of Family Medicine Rowan University School of Osteopathic Medicine Stratford New Jersey USA), Daniel Rodger (0000-0002-2121-7167, Institute of Health and Social Care, School of Allied and Community Health London South Bank University London UK), Adam Omelianchuk (0000-0003-3241-2870, Center for Medical Ethics and Health Policy at Baylor College of Medicine Houston Texas USA) |
| Year | 2024 |
| Volume | 38 |
| Issue | 4 |
| Pages | 308-315 |
| Publication date | 2024-05-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Bioethics (JOURNAL) |
| Journal identifiers | ISSN: 0269-9702 • E-ISSN: 1467-8519 |
| Publisher | Wiley (PUBLISHER • GB) |
| DOI | 10.1111/bioe.13262 |
| PMID | 38183638 |
| OpenAlex | W4390637278 |
| Language | EN |
| Citations received | 2 |
Preclinical xenotransplantation research using genetically engineered pigs has begun to show some promising results and could one day offer a scalable means of addressing organ shortage. While it is a fundamental tenet of ethical human subject research that participants have a right to withdraw from research once enrolled, several scholars have argued that the right to withdraw from xenotransplant research should be suspended because of the public health risks posed by xenozoonotic transmission. Here, we present a comprehensive critical evaluation of the claim that xenotransplant recipients should be required to waive their right to withdraw from lifelong biosurveillance. We conclude that if xenotransplantation requires participants to waive their right to withdraw, then clinical trials may not be justifiable, given the ethical and legal obstacles involved with doing so. Consequently, if clinical trials are permitted with a right to withdraw, then they may pose a significant public health risk
Bioethics · Clinical trial · Economic shortage · Human rights · Pathology · Political science · Right to health · Xenotransplantation · Law · Medicine · Neuroethics, Human Enhancement, Biomedical Innovations · Pluripotent Stem Cells Research · Xenotransplantation and immune response · Surgery · Transplantation
| Unique citing works | 2 |
|---|---|
| Citations per year | 2 |
| Citation span | 2025 - 2026 (2) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 2 |